Caribou Biosciences (NASDAQ:CRBU) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Caribou Biosciences (NASDAQ:CRBU) issued its quarterly earnings data on Monday. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01, Zacks reports. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Caribou Biosciences Price Performance

NASDAQ:CRBU traded down $0.06 on Monday, reaching $1.11. The stock had a trading volume of 859,858 shares, compared to its average volume of 1,655,743. Caribou Biosciences has a 12-month low of $1.01 and a 12-month high of $7.61. The company has a market cap of $100.06 million, a price-to-earnings ratio of -0.67 and a beta of 2.34. The firm’s fifty day moving average is $1.43 and its two-hundred day moving average is $1.81.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CRBU. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Bank of America reduced their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Citigroup lowered their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Caribou Biosciences currently has a consensus rating of “Buy” and an average price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.